Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-β and a contrasting decrease in p27(Kip1 1)

Gynecologic Oncology

Volumn 78, Issue 2, 2000, Pages 113-122

  Farley, John ^a   Gray, Karen ^b   Nycum, Lawrence ^c,d   Prentice, Margaret ^d   Birrer, Michael J ^c,d   Jakowlew, Sonia B ^d  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinogenesis; Endocervix; p27(Kip1); TGF

Indexed keywords

POLYCLONAL ANTIBODY; PROTEIN P27; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE ENDOCERVIX;

EID: 0033838515     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5879     Document Type: Article

References (73)

1. Cancer statistics
2. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix
3. Anatomy and Histology of the Cervix
4. Epidemiology of Cervical Cancer: Overview
5. Cervical intraepithelial glandular neoplasia (adenocarcinoma in situ and glandular dysplasia). A correlative study of 23 cases with histologic grading, histochemical analysis of mucins, and immunohistochemical determination of the affinity for four lectins
6. Early stage adenocarcinoma of the uterine cervix: Histopathologic analysis with consideration of histogenesis
7. Cervical glandular atypia associated with squamous intraepithelial neoplasia: A premalignant lesion?
8. Human papillomavirus DNA in adenocarcinoma in situ, microinvasive adenocarcinoma of the uterine cervix and coexisting cervical squamous intraepithelial neoplasia
9. Human papillomavirus mRNA expression in adenocarcinoma in situ of the uterine cervix
10. The topography and invasive potential of cervical adenocarcinoma in situ, with and without associated squamous dysplasia
11. Monoclonal antibodies Ki-67 and MIB 1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin-fixed material
12. Quantitative image analysis of MIB-1 ractivity in inflammatory, hyperplastic, and neoplastic endocervical lesions
13. Cell cycle control and cancer
14. Transforming growth factor-beta
15. The TGF-β family and its composite receptors
16. Cloning of a receptor that forms a heteromeric complex with the TGF-β type II receptor
17. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase
18. Concomitant loss of transforming growth factor-β receptors type I and type II in TGF-β-resistant cell mutants implicates both receptor types in signal transduction
19. p27(Kip1): A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
20. p27(Kip1), a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest
21. P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
22. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer
23. Aberrant p27(Kip1) expression in endocrine and other tumors
24. Localization and expression of p27(Kip1) in multistage colorectal carcinigenesis
25. Transforming growth factor-β1 induces apoptosis through down-regulation of c-myc gene overexpression of p27(Kip1) protein in cervical carcinoma
26. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF β): Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β
27. Inhibition of growth by transforming growth factor-β following fusion of two non-responsive human carcinoma cell lines
28. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progress to tumorigenicity and transforming-beta independence without inactivating the p53 tumor suppressor gene
29. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
30. Microsatellite instability and mutations of the TGF-β type II receptor gene in colorectal cancer
31. Mis-sense mutations of the transforming growth factor β type II receptor in head and neck squamous carcinoma cells
32. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
33. Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition
34. Loss of functional cell surface transforming growth factor β (TGF-β) type I receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia
35. TGF-β signaling and cancer: Structural and functional consequences of mutations in smads
36. Genetic changes in the transforming β type II receptor gene in human gastric cells: Correlation with sensitivity to TGF-β
37. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
38. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells
39. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor β1
40. Effects of TGF-β on the immune system: Implications for cancer immunotherapy
41. Regulation of immune responses by TGF-β
42. Transforming growth factor-beta receptors in human cancer cell lines: Analysis of transcript, protein and proliferation
43. Immunohistochemically detectable TGF-β is associated with malignancy in thyroid epithelial neoplasia
44. Immunohistochemical study of epidermal growth factor and transforming growth factor-β in the penetrating type of early gastric cancer
45. Transforming growth factor-β and transforming growth factor β receptor expression in human meningioma cells
46. Immunohistochemical staining for transforming growth factor-β1 associates with disease progression in human breast cancer
47. Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro
48. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival
49. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma
50. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression
51. Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: Evidence for paracrine and autocrine action
52. Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma
53. Altered expression of transforming growth factor-β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix
54. Differential transforming growth factor-β secretion in adenocarcinoma and squamous cell carcinoma of the cervix
55. 1 cyclins and cyclin-dependent kinases
56. Transforming growth factor β and cell cycle regulation
57. Neoplastic transformation of the endocervix associated with downregulation of lactoferrin expression
58. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, Rb, and EGFR in cervical carcinomas
59. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggessive colorectal carcinomas
60. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor-βb
61. Modulation of c-myc by transforming growth factor-β in human colon carcinoma cells
62. Suppression of the EGF-dependent induction of c-myc proto-oncogene expression by transforming growth factor β in a human breast carcinoma cell line
63. TGF-β inhibits growth factor-induced DNA synthesis in hamster fibroblasts without affecting the early mitogenic events
64. 1 to S transition, but not activation of human B lymphocytes
65. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
66. Frequent aberration of the transforming growth factor-β receptor II gene in cell lines but no apparent mutation in pre-invasive and invasive carcinomas of the uterine cervix
67. TGF-β signal transduction
68. Cancer of the uterine cervix in Norway by histological type, 1970-84
69. Squamous and adenocarcinoma of the uterine cervix: A comparison using routine data
70. Prognosis of the adenocarcinoma of the cervix uteri: A comparative study
71. Cancer prognostics: Past, present and p27